default

In memorium: Prof Sir Roy Calne

Prof Sir Roy Calne, who carried out Europe’s first liver transplant, died aged 93 in Cambridge late on Saturday evening. He performed the game changing operation on 2nd May 1968 at Addenbrooke’s hospital in Cambridge, and was responsible for other surgical ‘world firsts’.

In 1978, he became the first doctor to use an immunosuppressant, which was found to be effective in reducing organ rejection.

His work on liver transplants offered thousands of people with end-stage liver disease a normal life, the Royal Society said.

Cambridge University Hospitals NHS foundation trust said Sir Roy was professor of surgery between 1965 and 1998, performing Cambridge’s first kidney transplant in 1965 and Europe’s first liver transplant three years later. Addenbrooke’s hospital named its specialist transplant unit after the medic, honouring his “world firsts”, and a plaque was placed at the entrance.

At the time, Prof Chris Watson credited the surgeon with putting “Cambridge on the map as an international centre for excellence”.

In 2021, it was the only transplant centre to perform all abdominal organ transplants, with more than 350 conducted each year, Watson added.

news and updates Liver News
BSg-logo.png
July 09, 2025

BSG Travelling Fellowship – AASLD and visit to the National Institute of Health in Baltimore

This fellowship aims to offer an opportunity for a trainee who has a strong interest in Hepatology to attend AASLD’s Liver Meeting in Washington DC, USA in November 2025 to see the latest research and clinical updates in Hepatology.

News Area news and updates
BSg-logo.png
May 07, 2025

Help Shape the Future of GI Physiology – National Data Collection Open (May–June 2025)

The second National Data Collection for GI Physiology services will run from Monday 12th May to Friday 6th June 2025.

news and updates IBD News
BSg-logo.png
May 01, 2025

BSG Inflammatory Bowel Disease Surveillance Guideline 2025

Our newly updated guideline for colorectal surveillance for patients with IBD is now available, providing a comprehensive road map for evidence-based, expert management of the whole pathway to try and prevent or detect bowel cancer early for this higher risk patient group.